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Abstract
Background: High throughput parallel sequencing, RNA-Seq, has recently emerged as an appealing alternative to
microarray in identifying differentially expressed genes (DEG) between biological groups. However, there still exists
considerable discrepancy on gene expression measurements and DEG results between the two platforms. The
objective of this study was to compare parallel paired-end RNA-Seq and microarray data generated on 5-azadeoxy-
cytidine (5-Aza) treated HT-29 colon cancer cells with an additional simulation study.
Methods: We first performed general correlation analysis comparing gene expression profiles on both platforms.
An Errors-In-Variables (EIV) regression model was subsequently applied to assess proportional and fixed biases
between the two technologies. Then several existing algorithms, designed for DEG identification in RNA-Seq and
microarray data, were applied to compare the cross-platform overlaps with respect to DEG lists, which were further
validated using qRT-PCR assays on selected genes. Functional analyses were subsequently conducted using
Ingenuity Pathway Analysis (IPA).
Results: Pearson and Spearman correlation coefficients between the RNA-Seq and microarray data each exceeded
0.80, with 66%~68% overlap of genes on both platforms. The EIV regression model indicated the existence of both
fixed and proportional biases between the two platforms. The DESeq and baySeq algorithms (RNA-Seq) and the
SAM and eBayes algorithms (microarray) achieved the highest cross-platform overlap rate in DEG results from both
experimental and simulated datasets. DESeq method exhibited a better control on the false discovery rate than
baySeq on the simulated dataset although it performed slightly inferior to baySeq in the sensitivity test. RNA-Seq
and qRT-PCR, but not microarray data, confirmed the expected reversal of SPARC gene suppression after treating
HT-29 cells with 5-Aza. Thirty-three IPA canonical pathways were identified by both microarray and RNA-Seq data,
152 pathways by RNA-Seq data only, and none by microarray data only.
Conclusions: These results suggest that RNA-Seq has advantages over microarray in identification of DEGs with
the most consistent results generated from DESeq and SAM methods. The EIV regression model reveals both fixed
and proportional biases between RNA-Seq and microarray. This may explain in part the lower cross-platform
overlap in DEG lists compared to those in detectable genes.
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Background
In recent years, RNA-Seq emerged as an appealing alter-
native to classical microarrays in measuring global geno-
mic expressions [1,2]. The RNA-Seq technology has
been applied to many human pathological studies such
as prostate cancer [3], neurodegenerative disease [4],
retina defection [5], and colorectal cancer [6]. Gene
detection in RNA-Seq, unlike microarray, is not depen-
dent on probe design; rather it relies on short nucleotide
reads mapping which can attain exceedingly high resolu-
tion. Furthermore, the RNA-Seq gene counts cover a
larger dynamic range than microarray probe hybridiza-
tion based design. On the other hand, microarray tech-
nology is still widely used because of lower costs and
wider availability [7]. Previous studies comparing parallel
RNA-Seq with microarray data have reported good cor-
relation between the two platforms [1,8-13]. While clas-
sical correlation approaches can evaluate the strength of
the association between the two platforms, they have
been insufficient in gauging proportional and fixed
biases between the two platforms. Given the uncertain-
ties in measuring gene expressions for both platforms,
we have therefore applied the Errors-In-Variables (EIV)
regression model [14]. The EIV model is a more suitable
regression method for this type of platform comparison
because (1) it reflects measurement errors from both
platforms, (2) its goodness-of-fit measure reflects the
Pearson correlation, yet with the added advantages of
(3) providing a measure for fixed bias and, a measure
for proportional bias [15].
A major rationale for conducting global transcriptomic
studies is to identify genes that are differentially expressed
between two or more biological conditions. In previous
comparisons of the differentially expressed gene (DEG)
lists generated using parallel RNA-Seq and microarray
data, the biological groups that were studied were often
very different (e.g. liver vs. kidney, or malignant breast cell
line vs. normal breast cell line) [1,8]. In the current study,
parallel sets of RNA-Seq and Affymetrix microarray data
were generated on a single HT-29 colon cancer cell line
that was treated with and without 5-aza-deoxy-cytidine (5-
Aza), a DNA methylation enzyme inhibitor. The concen-
trations of 5-Aza used in the present study (0 μM, 5 μM
and 10 μM), approximated or exceeded the concentration
previously reported to reverse hypermethylation of the
SPARC (EMBL: ENSG00000113140) gene promoter and
reverse suppression of SPARC mRNA expression in HT-
29 cells [16]. In this study, paired ends 100bp RNA-Seq
data was generated as opposed to single end RNA-Seq
data described in similar reports [1,8,10,11,13]. Moreover,
most of the previous studies comparing the two platforms
were usually based on one or two DEG detection methods,
which were relatively outdated or not inclusive [7,15,17].
Our study surveyed an array of currently used algorithms
to identify DEGs in parallel for both microarray and
RNA-Seq data. We sought to determine which pair of
microarray and RNA-Seq algorithms would yield the
largest overlap in the DEG lists under the same statistical
significance level. A simulation study was further con-
ducted using published parallel RNA-Seq and microarray
datasets [1], to assess the consistency of different DEG
methods across platforms and their ability in identifying
true positives. Quantitative reverse transcriptase polymer-
ase chain reaction assays (qRT-PCR) was used to assay
expression of the SPARC gene and other DEGs selected by
using 1) both datasets, 2) RNASeq data only and 3) micro-
array data only. Finally we determined which Ingenuity
Pathways Analysis (IPA) canonical pathways were identi-
fied by 1) both datasets, 2) RNASeq data only and 3)
microarray data only.
Methods
5-Aza treatment of HT-29 cells
The HT-29 (ATCC) colon cancer cell line was main-
tained in DMEM supplemented with 10% fetal bovine
serum, 1% kanamycin, streptomycin-penicillin, and incu-
bated at 37° C and 5% CO2. Three replicative 150 mm
cultures were treated with: 1) dimethyl sulfoxide (vehicle
alone, 0 μM 5-Aza); 2) 5 μM 5-Aza and 3) 10 μM 5-Aza;
for five days. These 5-Aza concentrations are similar and
greater than the 5-Aza concentration previously reported
to increase apoptosis, alter genome methylation as well
as mRNA gene expression in HT-29 cells [16]. The HT-
29 cells were washed with phosphate buffered saline on
the plate prior to scraping and centrifuging the cells.
Total RNA was extracted separately from each of these
nine cultures using TRI Reagent according to the manu-
facturer’s recommendations. The RNA quality was
assessed using an Agilent 2100 Bioanalyzer (Agilent
Tech., Palo Alto, CA) to have a RNA Integrity Number
score ≥ 7. Each of the nine RNA samples was used to
generate parallel RNA-Seq, microarray and qRT-PCR
data.
Illumina RNA-Seq data
Aliquots (1 μg) of nine RNA samples (triplicate samples
for each of three experimental conditions), were sub-
jected to paired-ends 100 bp Illumina sequencing. The
RNA-Seq libraries were prepared and sequenced at Cold
Spring Harbor Laboratories using the TruSeq RNA
Sample Preparation Kit (Illumina Inc., San Diego, CA).
In brief, mRNA was purified and fragmented, followed
by cDNA synthesis with random hexamers. This pro-
duct then underwent end repair, adapter ligation, and
size selection using AMPure XP beads (Beckman Coul-
ter Inc., Brea, CA) to isolate DNA templates of 320nt
fragments and to remove excess adapters. The cDNA
was PCR amplified. Each library was sequenced using
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Illumina 2000 sequencer (Illumina Inc., San Diego, CA)
on 2 lanes of the flow cell. Between 41 and 88 million
reads were generated for each of the RNA samples. The
sequences were filtered using FASTX-Toolkit [18] to
remove sequences with low Phred scores (~ first 3
nucleotides). The short reads fastq files were processed
using Tophat (v2.0.1) [19] and mapped to the reference
Ensembl human genome 19 using default settings for
paired reads. Cufflink program (version 1.3.0) [20] or
HTSeq-count (v 0.5.3p7) [21] were subsequently
employed to convert aligned short reads (BAM format)
into Fragments Per Kilobase of exon model per Million
mapped fragments (FPKM) or raw gene counts. In the
following step, a filter procedure was applied to remove
gene entries with max alignment number of < 10 in all
three replicates of the experimental groups (control or
0 μM, 5 μM and 10 μM 5-Aza). The RNA-Seq data
were deposited in NCBI’s Gene Expression Omnibus
database with accession number GSE41588.
Affymetrix microarray data
Aliquots (150 ng) of the same nine RNA samples were
each labeled (single color), hybridized to Affymetrix
hgu133plus2.0 (Affymetrix Inc., Santa Clara, CA) arrays,
and the arrays were scanned in the Stony Brook University
DNA Microarray Core Facility, according to the manufac-
turer’s protocol. Note each RNA sample was hybridized to
a separate microarray chip. Microarray data were prepro-
cessed using Bioconductor’s affy package followed by a
custom filter procedure to retain the probe entries that
were present in all three biological triplicates of one
experimental group (control or 0 μM, 5 μM and 10 μM
5-Aza). RMA normalization was applied to scale the repli-
cates to a comparable range. If multiple probes on the
array corresponded to a single gene, the probe with the
highest intensities was used to represent the gene inten-
sity. The microarray data have been deposited in NCBI’s
Gene Expression Omnibus and are accessible through
GEO Series accession number GSE41364.
Platform comparison based on gene expression levels
and correlations
General between-platform association analysis was
applied to compare RNA-Seq with microarray data pro-
files. This includes a detectable gene determination for
each group after the filter procedure, in which detect-
able genes were identified and compared respectively
between the two platforms. In addition, the general gene
expression profiles from RNA-Seq or microarray were
examined in a scatter plot with Pearson and Spearman
correlation coefficients calculated for all the genes
(including those removed by the filtering procedure).
Detectable genes which are RNA-Seq exclusive were
compared to the overlapped ones using expression
intensity histograms. This analysis was performed to
verify the sensitivity of RNA-Seq technology in detecting
genes expressed at low levels.
Errors-In-Variables (EIV) regression model
Both normalized microarray data and RNA-Seq FPKM
values were transformed into log2 scale and subsequently
converted to unit-free ratios by dividing a pre-selected
housekeeping gene, ZNF311(EMBL: ENSG00000197935).
This gene was selected based on its moderate intensity
and consistent expression levels (rank of expression inten-
sity) across all samples on both platforms. We did not use
GAPDH (EMBL: ENSG00000111640) as housekeeping
gene because it is highly expressed. In our experiment a
moderate expressed gene is more suitable as the reference
for all measured genes.
We subsequently constructed a linear functional
Errors-In-Variables (EIV) regression model based on the
log2 scaled, normalized values between RNA-Seq (Y)
and Microarray (X) as follows:
Yij = α + βξi + ∈ij,∈ij ∼ N(0,λσ 2∈ )
Xij = ξi + δij, δij ∼ N(0, σ 2δ )
λ =
σ 2∈
σ 2δ
(1)
Here Yij denotes the normalized value of RNA-Seq
expression for gene i and sample j and Xij represents
the normalized microarray expression intensity. More-
over, ξi is the expected value of Y; ∈ij and δij are inde-
pendent platform measurement errors with mean zero
and variances σ 2∈ and σ
2
δ . A prerequisite of this EIV
model is the homoscedasticity assumption and in prac-
tice we removed the top 1% of genes with the largest
variation and examined the remaining genes using
Levene’s test [22] to ensure equal error variances on
both platforms. The ratio of error variances l is estim-
able when we have multiple observations from the same
sample, which we fortunately do in this study with 3
replicates per sample. When the errors are normally dis-
tributed we can obtain the point estimators of the
model parameters via the maximum likelihood method
[23]. The confidence intervals for the regression slope
and intercept can be obtained via the bootstrap resam-
pling method.
In our study, an EIV regression model was constructed
for each of the three experimental HT-29 cell groups
(control or 0 μM, 5 μM, and 10 μM 5-Aza) and the R
rootSolve package (v. 1.6.3) was used to compute the
point estimators for each regression model. The boot-
strap resampling method with 1000 times resampling
were performed to derive the corresponding 95% confi-
dence interval for the regression intercept a and the
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regression slope ß as an estimate of the fixed and the
proportional bias respectively. Statistically, the confi-
dence interval of a covering 0 indicates an absence of
fixed bias; whereas the confidence interval of ß encom-
passing 1 implies the absence of proportional bias.
DEG algorithms for microarray and RNA-Seq data
The T-test with Benjamini-Hochberg correction [24],
SAM [25] and eBayes [26] algorithms were applied to
the filtered Affymetrix microarray data to generate DEG
lists ( > 2-fold, FDR ≤ 0.05) for the following two pair-
wise comparisons: 1) 5µM vs. 0µM 5-Aza groups and 2)
10µM vs. 5µM 5-Aza groups, respectively. The Cuffdiff
[20], SAMSeq [27], DESeq [28], baySeq [29] algorithms
were applied to the filtered RNA-Seq data to generate
DEG lists based on the same cutoff (> 2-fold or <0.5,
FDR ≤ 0.05). NOISeq [30] was applied to the RNA-Seq
data and the DEG list was subsequently filtered for a
threshold of (> 2-fold or <0.5). The popular edgeR algo-
rithm [31] was not included since it closely resembled
the DESeq algorithm [28].
Comparing DEG algorithms using simulated data
In our simulation study, we designed a simulation method
which generated consistent RNA-seq and microarray data
in comparing DEG algorithms of the two platforms. The
RNA-Seq and microarray simulations were built upon par-
allel RNA-Seq and microarray datasets reported previously
by Marioni et.al. (GSE11045) [1]. For this simulated analy-
sis we could not apply the Cuffdiff algorithm because the
previously published RNA-Seq data was reported only as
raw gene counts without exon level information.
Assessment of error in the microarray data was con-
ducted using the model described previously by Rocke
and Durbin [32] in which observed gene expression is
modeled as y = α + ueη + ε , where h, ε are normal error
term and u is true intensity. A variance stabilizing trans-
formation was applied as previously described [33] as
shown in equation (2):
g(y) = ln
(
y − α +
√
(y − α)2 + c
)
(2)
Here y is the probe expression intensity, a denotes the
mean of background noise, c stands for sd (ε) /sd (eη) ; h
and ε are normally distributed error terms. In our simula-
tion, RMAexpress [34] was used in noise correction, the
genes expressing at the bottom 1% level were used to
estimate sd(ε) , and the log transformation of genes
expressing at the top 1% level (after correction for noise)
were used to estimate sd (η) . The mean of background
noise — a, was estimated by subtracting from the uncor-
rected mean intensity of the genes expressing at the bot-
tom 1% level, the noise corrected mean intensity of the
genes expressing at the bottom 1% level. It is easy to
solve that:
y − α = ueη + ε = e
2g(y) − c
2eg(y)
By averaging across the ln
[(
e2g(y) − c) /2eg(y)], we can
approximately eliminate the effect of h and ε; and the
transformed data could then be used to build an empiri-
cal distribution of u. The true expression levels of simu-
lated genes were sampled from this empirical distribution
in such a way that: a histogram of true data was gener-
ated using 500 bins at first step; a simulated gene was
then assinged to a bin based on the frequency with a
small turbulance added to its value. Uniform distribution
(ranging the length of the bin) was assumed to the turbu-
lance term to differentiate genes in the same group. As a
result, the transformed expression level of a gene at a
certain x% quantile of a given sample is equal to the
same x% quantile of g(y) in terms of distribution + a
small turbulance. The turbulance added same effect of
variation to every gene because of the variance stablizing
transformation.
The RNA-Seq data were fitted in a negative binomial
model as described by Kvam [35]. The mean expression
level l was sampled from a gamma distribution whose
parameters were determined by fitting the true data with
maximum likelihood method; similarly, the over-disper-
sion parameter  was also generated from a gamma dis-
tribution described before [29]. In practice, the
distribution of l was slightly rescaled to the range of the
real data. Subsequently, we sampled both microarray g(y)
and RNA-Seq l of 10,000 genes from each corresponding
distribution with a strict rule on quantile consistency
(any gene of the a percentile of one distribution shall
have the same quantile in the other dataset). In reality,
sample percentile converge to distribution percentile
when sample size is large, therefore a Spearman correla-
tion of 1 was approximated in our simulated data sets
across platforms.
Pre-defined significant DEGs were randomly sampled
so that the log fold changes of these preset DEGs were
generated from a mixed normal distribution where the
probabilities of being up and down regulated were both
equal. Moreover, in our analysis, the absolute expectation
of log fold changes and standard errors for up and down
regulated genes were set to be the same.
In practice, we generated 10 sets of simulated data in
practice with 5 replicates included in both treatment and
control group and 1000 random selected genes were pre-
set to be differently expressed in different levels using a
method of 95% minimum fold change such that the 1000
preset bona fida DEGs were generated with their fold
changes following a log-normal distribution with 95% of
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the 1000 genes having their fold changes above the given
level. We implemented a total of seven algorithms in our
study, namely T test, SAM and eBayes on microarray
data and baySeq, DESeq, SAMseq, NOISeq for RNA-Seq
data.
In this work, the sensitivity and false discovery rates
(FDR) were firstly evaluated for each DEG method under
the 95% minimum fold change of 2 for preset DEGs and
FDR cutoff of 0.05. For NOISeq method, a q = 0.8
(recommended by NOISeq author) criterion was used
due to the absence of FDR control in this method. We
further evaluated the sensitivity and false positive rate of
each DEG algorithm by varying the differential signifi-
cance levels of the preset 1000 genes using 95% mini-
mum fold change method. Specifically, a range of values
from 0.5 to 4 by an increment of 0.5 were used to gener-
ate the simulated DEGs.
qRT-PCR analysis of control HT-29 RNA samples vs. 5 μM
5-Aza treated HT-29 RNA samples
Reverse transcription was performed on 5 μg aliquots of
each of the six RNA samples using the SuperScript III
First-Strand Synthesis System for RT-PCR (Invitrogen Life
Technologies, Grand Island, NY) according to the manu-
facturer’s protocol. QRT-PCR was initially performed on
serial dilutions of the cDNA for each Taqman assay kit
using Taqman assay kits (Invitrogen Inc., Carlsbad, CA) in
order to confirm that each of the assays were conducted
in the linear range and the slopes of the threshold cycle Ct
when plotted against the dilution were the same for all of
the assays. Thirteen genes were selected by the majority
vote of platform specific DEG detection methods and are
categorized into 3 groups, which are: 1) commonly identi-
fied on RNA-Seq and microarray datasets; 2) RNA-
Seq data only and 3) microarray data only. This list of
genes, with the additional SPARC and GAPDH (EMBL:
ENSG00000111640), and the corresponding commercial
Taqman assays are listed in Additional file 1. The qRT-
PCR assays were conducted in triplicate for each RNA
sample. The ΔCt values (Ct for GAPDH - Ct for the test
gene) were calculated for each RNA sample. The Student
t-test was used to analyze whether there was a significant
difference between the mean ΔCt for the control vs. the
5 μM 5-Aza treated HT-29 groups, with a threshold signif-
icance level of 0.05. The fold change in gene expression
was calculated as 2-ΔΔCt (ΔΔCt = ΔCt of 5-Aza group -
ΔCt of control group).
Ingenuity Pathway Analysis of microarray and
RNA-Seq data
Based on the results of the simulation, we performed IPA
analysis (Ingenuity® Inc, Redwood city, CA) on up-regu-
lated DEGs (5 µM vs. 0 µM 5-Aza) and down-regulated
DEGs respectively. 5 DEG lists were generated by the
SAM, eBayes, Cuffdiff, DESeq and baySeq algorithms.
Significantly enriched canonical pathways were selected
based on the p value cutoff of 0.05 and included gene
number > 3 [36].
Results
General association between the two platforms
A total of 13006, 13855 and 13330 genes were detected
respectively for the 0µM, 5 µM and 10 µM 5-Aza HT-
29 microarray datasets, whereas 16219, 18581 and
17044 genes were identified on RNA-Seq for the 3
groups. On average, the Illumina RNA-Seq detected
~29.0% more genes than its microarray counterpart and
a significant portion (~22.1%) of the RNA-Seq specific
genes did not have corresponding probe sets on the
array. The overlap rates of the genes detected by both
RNA-Seq and microarray datasets for the 0 μM, 5 μM
and 10 μM 5-Aza HT-29 cultures, respectively, ranged
between 66.8-68.6% (Figure 1A). We further profiled the
expression pattern of all genes from both platforms and
observed a general linear relationship between the two
data sources. Both Pearson and the Spearman correla-
tion coefficients were evaluated for each group and the
results (Pearson correlation r = 0.81 ~ 0.83, Spearman
correlation rs = 0.87 ~ 0.89, P value << 1×10
-10) indi-
cated a strong correlation between the two platforms
(Figure 1B). This result is by and large consistent with
previous reports in similar comparative settings
[1,9-11,13]. We further examined the widely-reported
sensitivity advantage of RNA-Seq over microarray plat-
form. Group-wise density histograms were generated to
examine the distribution of the commonly detectable
genes and those having corresponding probes on the
array yet are exclusively identified by RNA-Seq (Figure
1C). The histogram clearly showed disparate peaks
between the two categories of genes with the overlapped
ones forming a higher peak at the upper level of the
expression scale and the microarray bereft genes mainly
distributed at the lower end of the axis. This observation
indicates that RNA-Seq may be superior to the microar-
ray in detecting genes expressed at low levels.
Applying EIV model for platform comparison
An Errors-In-Variables regression model was built to
investigate the consistency between normalized microarray
gene abundances and the normalized FPKM genomic
intensities from RNA-Seq platform with both measure-
ments in log2 scale. Using the maximum likelihood esti-
mation of the EIV model, we obtained a linear relationship
of the gene expression profiles between RNA-Seq and
microarray for each experimental group (Figure 2). In
each regression model, the variance ratio l was calculated
numerically and the optimal value was used to determine
the slope and intercept of the corresponding regression
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Figure 1 Expressional consistency between RNA-Seq and microarray data. A. Detectable genes reported by each technology based on a
common filter procedure (See Methods). Venn diagrams of detectable genes are shown 3 experimental conditions (0 µM, 5 µM and 10 µM)
respectively, and overlap rates are calculated by dividing number of commonly detectable genes by the union. B. By-group scatter plot
depicting the expression profiles of all genes. Log2 transformed FPKM values from RNA-Seq and log2 scaled microarray gene intensities
(normalized) are used in the scatterplot. We added 1 to FPKM value before log2 transformation to facilitate calculation. Commonly detected
genes are shown in red color while platform exclusive genes are denoted in black. Both Pearson correlation coefficients (PCC) and Spearman
correlation coefficients (SCC) were calculated based on all gene entries (except for those not having probe names on the array or RNA-Seq
reference genome). C. By-group expressional density histogram for both commonly detectable genes and RNA-Seq specific ones. The x-axis
denotes the RNA-Seq FPKM value (log2 scale) distribution and y-axis shows the frequency of genes within each category. Commonly detectable
genes are depicted in black while RNA-Seq exclusive genes are shown in grey color.
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line. Based on the observation across all 3 groups, we
found that the estimated fixed bias αˆ ranging from -0.12
to -0.33 with the corresponding 95% bootstrap confidence
intervals for a not covering 0, indicating the existence of
the fixed bias of measurements between the two platforms.
Moreover, a clear deviation from the regression model and
the reference Y = X line was observed (Figure 2). The esti-
mated regression slope βˆ , representing the proportional
bias, ranged from around 1.38~1.52, with the correspond-
ing 95% bootstrap confidence intervals for b excluding 1
indicating the presence of proportional bias between the
two platforms as well. This infers that the changes of
microarray measured gene expression at per unit level do
not equate to the same level of unit change on the RNA-
Seq platform, a result possibly arising from the different
signal quantification mechanisms between the two tech-
nologies (short reads counts versus fluorescence intensity).
Comparison of DEG algorithms applied to experimental
microarray and RNA-Seq HT-29 data
Three microarray DEG algorithms (T-test, SAM, eBayes)
and five RNA-Seq algorithms (Cuffdiff, SAMSeq, DESeq,
baySeq and NOISeq) were applied to the experimental
HT-29 microarray and RNA data, respectively (See Addi-
tional file 2). The threshold was set at fold-change > 2 or
less than 0.5 and a false discovery rate ≤ 0.05 for all of the
eight algorithms except NOISeq. Since setting a fold
change was not an option for NOISeq, we set a threshold
of q = 0.8 and then subsequently filtered the selected
genes with a threshold of fold-change > 2 or less than 0.5.
Treatment of HT-29 cells with 5 μM 5-Aza (compared to
the control HT-29 cells) resulted in up-regulation (↑) and
down-regulation (↓) of genes. The T-test identified 392↑
148↓, SAM identified 794↑ 256↓ and eBayes identified
782↑ 259↓ using the same microarray data (~13,000
detectable genes). Cuffdiff found 1149↑ 558↓, SAMSeq
found 2262 ↑ 282↓, DESeq found 1840↑ 300↓, baySeq
found 2013↑ 293↓, and NOISeq identified 673↑ 151↓
using the same RNA-Seq data (~17,000 detectable genes).
All of the algorithms demonstrated an overall upregulation
of gene expression after treatment of 5 μM 5-Aza. This is
consistent with the concept that 5-Aza treatment reverses
hypermethylation of gene promoters in HT-29 colon can-
cer cells and thus activates corresponding genes. However,
activation of SPARC gene expression, which was pre-
viously reported after treatment of HT-29 cells with 4 μM
5-Aza [16], was observed in the RNA-Seq data only, and
not in the microarray data.
The effect of increasing the concentration of 5-Aza from
5 μM to 10 μM 5-Aza was also analyzed using the eight
algorithms and the same threshold parameters. The T-test
identified 0↑ 2↓, SAM identified 13↑ 285↓ and eBayes
identified 41↑ 278↓ using the same microarray data
(~13,000 detectable genes). Cuffdiff detected 15↑ 485↓,
SAMSeq detected 0↑ 626↓, DESeq detected 43↑ 389↓, bay-
Seq detected 58↑ 424↓, and NOISeq detected 95↑ 123↓
using the same RNA-Seq data (~17,000 detectable genes).
With the exception of the T-test and NOISeq, the remain-
ing six algorithms detected an overall down-regulation in
gene expression when the concentration of 5-Aza was
Figure 2 EIV Regression Model Comparing Microarray and RNA-Seq Gene profiles. EIV regression model is constructed for independent
variable (microarray normalized gene intensities in log2 unit-free scale) and dependent variable (RNA-Seq FPKM values in log2 unit-free scale) for
each of the experimental groups (5 µM, 10 µM and 0 µM) of HT29 samples. Log2 scaled unit-free normalized gene intensities are shown as grey
circles in the scatter plot and EIV regression line is drawn in bold black. For each of the plots, a dashed reference line of Y = X (corresponding
to perfect platform agreement) is also included to indicate the deviation of the real regression line from the reference. The estimated regression
equation is shown in the lower-right section of each plot. The 95% bootstrap confidence interval for the regression intercept and slope (a and
ß) are shown on the top of each plot.
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increased from 5 μM to 10 μM. This could reflect toxic
effects of 5-Aza at the higher 10 μM concentration.
The cross-platform overlap rates between the DEG
lists generated by each of the three microarray algo-
rithms with DEG lists generated by each of the five
RNA-Seq algorithms are summarized in Table 1. The
highest cross-platform overlap rates were achieved by
comparing the baySeq and DESeq generated DEG lists
using the RNA-Seq data, with the SAM and eBayes gen-
erated DEG results using the microarray data.
Comparison of DEG algorithms applied to simulated
microarray and RNA-Seq data
Simulated datasets were generated from independent par-
allel RNA-Seq and microarray datasets generated from
kidney tissue [1]. In this experiment, technical rather than
biological replicates were used to generate the data set. It
was not feasible to evaluate Cuffdiff using this method
since the data set only provided gene counts without exon
level information. The overlaps in the DEG lists are sum-
marized in Table 2. To be consistent with the thresholds
applied when these algorithms were applied to the experi-
mental HT-29 data, we used the 95% minimum fold
change method with FC level = 2 on preset positives and
FDR ≤ 0.05 for each algorithm (See Methods). Intra-
microarray platform comparisons revealed that the T-test
generated DEG list overlapped poorly with both the SAM
and the eBayes generated DEG lists. However, SAM and
eBayes DEG lists achieved 95% overlap with each other.
Intra-RNA-Seq platform comparisons revealed that bay-
Seq and DESeq DEG lists achieved 75.7% overlap with
each other, while the overlap percentages ranged between
46% and 54% for the remaining RNA-Seq algorithms. The
highest cross-platform overlap percentages (48-50%) were
observed between the SAM and eBayes microarray DEG
lists and the baySeq and DESeq RNA-Seq DEG lists. Not
surprisingly, the T-test DEG list overlapped poorly with
the results of all the RNA-Seq algorithms.
The sensitivity and the false discovery rate of each
method were also calculated in ten simulated runs for
the sake of accuracy evaluation. Based on the same sig-
nificance level (95% minimum fold change method: FC
cutoff ≤ 2 and FDR ≤ 0.05), we found that baySeq pro-
duced the highest sensitivity (52.6%) from RNA-Seq
while SAM achieves the best sensitivity (50.4%) among
microarray methods (Figure 3A). On the other hand, the
RNA-Seq DEG algorithms generally result in higher
FDRs (0.03~0.12) than their microarray counterparts
(< 0.01). A further simulation test was conducted by
changing the significance level of preset true positives.
We observed that with the increase of true positive fold
change (See Methods), the baySeq method continues to
outperform other algorithms while DESeq, slightly infer-
ior to baySeq, has been generally yielding good results,
too (Figure 3A). On the microarray side, the SAM con-
stantly achieves higher sensitivity than Ebayes and t-test.
As per FDR evaluation, NOISeq method performed the
worst among the four on FDR evaluation curve, particu-
larly at the lower fold change end (Figure 3B, Right);
The baySeq method, albeit more sensitive in calling true
positives, has relatively poorer performance in control-
ling FDR and this drawback becomes more remarkable
at higher fold change end (Figure 3B, Left). The specifi-
city of each method was also evaluated and all of them
were well above 99.9%.
qRT-PCR Results
We applied yet a third technology, qRT-PCR, to confirm
DEGs identified by the various microarray and RNA-Seq
algorithms (Table 3). The SPARC gene expression was
previously reported to be undetectable in control HT-29
cells but detectable in 4 μM 5-Aza treated HT-29 cells
using a qualitative gel-based RT-PCR method [16]. We
therefore conducted qRT-PCR assays on the control and
5 μM 5-Aza treated groups in this study on a selected
subset of DEGs, including the SPARC gene (Table 3).
Reversal of suppression of the SPARC gene was con-
firmed by qRT-PCR results since no SPARC gene
expression was detected in any of the three control HT-
29 RNA samples, but was detected in all three of the
Table 1 Cross-platform overlap in DEG lists using RNA-Seq and microarray HT-29 data.
Comparison (5-Aza) Methods Cuffdiff SAMSeq baySeq DESeq Noiseq
5 µM vs 0 µM T-test 25.8% 22.5% 24.5% 25.8% 29.7%
SAM 39.9% 39.9% 42.7% 44.5% 33.5%
Ebayes 39.5% 39.5% 42.2% 44.0% 33.3%
10 µM vs 5 µM T-test 0.5% 0.5% 0.6% 0.6% 0.0%
SAM 31.1% 30.2% 32.6% 34.2% 19.4%
Ebayes 30.3% 28.3% 31.9% 33.5% 19.1%
The cross-platform overlap rates (%)1 were calculated between the three microarray DEG algorithms (T-test, SAM, eBayes) and the five RNA-Seq algorithms
(Cuffdiff, SAMSeq, baySeq, DESeq, and NOISeq) as described in Methods. Comparisons were made to 1) measure the effect of treating HT-29 cells with 5 μM 5-
Aza compared to control cells and 2) the effect of increasing the 5-Aza concentration from 5 μM to 10 μM.
¹The DEG overlap rates were calculated by dividing the number of overlapped DEGs over the union number of DEGs identified from both methods. Overlap rates
higher than 40% are denoted in bold style.
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5 μM 5-Aza treated HT-29 samples on RNA-Seq plat-
form (Table 3). Overall qRT-PCR confirmed 75% of the
DEGs identified by both RNA-Seq and microarray data,
66% of the DEGs identified by only by RNA-Seq data
and 25% of the DEGs identified only by microarray data.
Biological function analysis of DEG lists generated by
microarray and RNA-Seq data
As shown in the outcome of the IPA analysis we per-
formed (see Additional file 3), the overlap rate for the IPA
canonical pathways selected by SAM and eBayes (microar-
ray algorithms) was 81.4% (35 of 43 pathways); the overlap
rate between the IPA canonical pathways was 52.1% (150
of 288 pathways) for DESeq and Cuffdiff, 91.4% (202 of
221 pathways) for DESeq and baySeq, and 48.0% (143 of
298 pathways) for baySeq and Cuffdiff. This is consistent
with the observation that Cuffdiff DEGs had a lower over-
lap rate with either DESeq (56.5%) or baySeq (52.9%),
while DESeq and baySeq has an overlap rate at 91.8%.
Based on this observation; we compared cross-platform
canonical pathways using the two microarray algorithms,
SAM and eBayes, and the two RNASeq algorithms, DESeq
and baySeq. All four of these algorithms identified 33
canonical pathways (See Table 4). 152 canonical pathways
were identified only by the two RNASeq algorithms,
DESeq and baySeq. No canonical pathways were identified
only by the two microarray algorithms.
Discussion
In order to evaluate the performance of paired-end RNA-
Seq data with a widely used commercial microarray plat-
form, we chose to generate parallel datasets in a well-
characterized experimental system, treatment of HT-29
colon cancer cells with 5-Aza, a DNA methyltransferase
inhibitor [16,37]. The 5-Aza concentrations were chosen
to approximate and exceed the concentration previously
reported to increase apoptosis and alter genome methyla-
tion as well as mRNA gene expression in HT-29 cells
[16]. Specifically reversal of hypermethylation of the
SPARC promoter and reversal of suppression of SPARC
gene expression were reported [16]. The RNA-Seq tech-
nology is rapidly advancing, hence paired-end rather than
single end RNA-Seq data were generated for this study.
We first examined the detection sensitivity for both plat-
forms. RNA-Seq detected more genes than microarray,
particularly among genes expressed at low levels. This
observation is consistent with previous studies [11,38].
The higher sensitivity of RNA-Seq can be attributed to its
detection mechanism based on single-read/nucleotide
resolution [39]. The microarray gene quantification results
largely depend on the accuracy of probe fluorescence
scanning; background signal and other confounding fac-
tors (e.g. stains on array surface) may conceal the real
genetic signal for a probe having a low abundance. In this
perspective, the difference in detection mechanism confers
a natural advantage to RNA-Seq comparing to microarray.
The genomic ranges covered by both platforms also differ
significantly. In addition, RNA-Seq detects all sequences
that are expressed and basically surveys all the known
genes provided by hg19 reference genome (N = 23,368),
whereas microarray only examines genes based on the pre-
designed probe sets included on the array (N = 18,209).
The correlation analysis confirmed strong general concor-
dance on the gene expression measurements across plat-
forms. Both Pearson and the Spearman correlation
coefficients between the two technologies were found well
above 0.8 with P values << 0.001 indicating the data were
in comparable quality to previously reported parallel
microarray and RNA-Seq datasets [1,11,40]. Furthermore,
the EIV regression model was applied since the classical
correlation based analysis is insufficient in gauging the
quantitative concordance of the two platforms and the
existence of random errors in both measurements ren-
dered the traditional ordinary least regression method
unsuitable in the current case. As per our study, the EIV
regression revealed the existence of both fixed and propor-
tional biases between the microarray and RNA-Seq plat-
forms. We found that the fixed bias plays a minor part
Table 2 Intra- and cross-platform comparison of DEG lists generated from simulated microarray and RNA-Seq data.
T-test Ebayes SAM baySeq DESeq SAMseq NOISeq
T-test 100.0%
Ebayes 5.1% 100.0%
SAM 4.8% 95.1% 100.0%
baySeq 3.0% 48.1% 49.6% 100.0%
DESeq 3.3% 48.7% 50.2% 75.7% 100.0%
SAMseq 3.4% 36.5% 37.0% 54.1% 51.9% 100.0%
NOISeq 3.3% 39.7% 39.7% 46.5% 50.4% 46.9% 100%
The simulations were carried out as described in Methods. The overlap percentages was calculated based on the percent of true positive DEGs (95% minimum
fold change method: FC ≥ 2 & FDR < = 0.05) identified by each of the three microarray algorithms (T-test, SAM, eBayes) and four RNA-Seq algorithms (SAMseq,
baySeq, DESeq, NOISeq).
¹The overlap rate was calculated based on true positive DEGs called by each method. The microarray and RNA-Seq cross-platform DEG overlap rates are shown in
bold style.
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Figure 3 Sensitivity and False Discovery Rate (FDR) curve plots for simulated data using each DEG method. Sensitivity (A.) or FDR (B.)
are calculated for 4 RNA-Seq DEG methods (SAMSeq, baySeq, DESeq, and NOISeq) and 3 microarray DEG algorithms (T-test, SAM, eBayes).
Method curves are shown in different colors (see figure legends) at each 95% minimum fold change level for pre-determined DEGs. Each fold
change on x-axis (in log2 scale) corresponds to the lower 5% fold change of normally distributed DEGs predefined in the simulation process
(See Methods).
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while the proportional bias is the major source of discre-
pancy between the two platforms (Figure 2). Basically, an
estimated fixed bias at -0.24 on the log2 scale reflected a
trivial baseline difference, whereas an estimated ~1.45 pro-
portional bias meant that a unit change on microarray
gene intensity on the log2 scale corresponded to about
1.45 units change for RNA-Seq on the log2 scale. This
regression model is consistent with the observation that
RNA-Seq was more sensitive and exhibited a larger
dynamic range than its microarray counterparts in mea-
suring the expression level of the same transcript.
Since the major goal of conducting global transcrip-
tomic studies is to identify genes that are differentially
expressed between two or more biological groups, this
Table 3 Confirmation of DEGs selected using both RNA-Seq and microarray data, RNA-Seq only and microarray only
by qRT-PCR.
Selected by1 Gene symbol FC2 qPCR P value3 FC2 microarray FC2 RNA-Seq
BOTH ALDH3A1 0.5 0.046 0.4 0.3
BOTH TGM2 1.6 0.762 0.4 0.3
BOTH IL8 3.2 0.002 3.7 3.4
BOTH IL1R1 2.6 0.033 4.5 3.9
Array IRF7 0.5 0.068 2.0 1.4
Array TAF11 1.8 0.045 1.7 1.5
Array PLCL1 1.2 0.469 0.7 0.8
Array LIPE 1.5 0.565 0.6 0.5
SEQ GGT1 6.1 0.043 1.0 2.6
SEQ GGT7 4.8 0.077 1.7 2.9
SEQ MAPK10 7.1 0.013 2.1 3.3
SEQ RPSA 0.5 0.009 1.7 0.4
SEQ EFNB1 2.0 0.605 0.8 0.4
SEQ SPARC4 INF <<0.001 0.8 INF
The predicted polarity of the fold change for each DEG is listed along with the qRT-PCR calculated fold change (2-ΔΔCt). The P-values were calculated based on
applying the T-test to ΔCt values of the control cells in comparison with the ΔCt values of the 5 μM 5-Aza treated cells (see Methods).
1Genes confirmed by RT-PCR as DEGs are marked in bold style (SEQ: Illumina RNA-Seq platform; Array: Affymetrix microarray platform)
2FC (fold change) is calculated as the group average of 5μM (5-aza-deoxycytidine)/Control, the normalized expression intensity value is used for microarray data
while FPKM values from Cufflinks program are used for RNA-Seq data.
3P value is calculated using unpaired t-test on qPCR data; Genes that are significantly different between two groups are highlighted in bold style.
4The SPARC gene (not part of the 13 genes list) was specially added into the qPCR experiment for validation. On both qPCR and RNA-Seq platforms, its
expression values in control group are all found to be zeros (below detection cutoff) whereas there are moderate expressions in 5μM group, therefore we
consider the fold change as infinite positive denoted by INF with infinite minimal p values.
Table 4 Pathways commonly detected by SAM, eBayes, DESeq and baySeq
Up-regulated
Atherosclerosis Signaling Human Embryonic Stem Cell Pluripotency
Interferon Signaling Bladder Cancer Signaling
LPS/IL-1 Mediated Inhibition of RXR Function Activation of IRF by Cytosolic Pattern Recognition Receptors
Antigen Presentation Pathway Factors Promoting Cardiogenesis in Vertebrates
Role of BRCA1 in DNA Damage Response Role of CHK Proteins in Cell Cycle Checkpoint Control
Hepatic Fibrosis/Hepatic Stellate Cell Activation FXR/RXR Activation
Type I Diabetes Mellitus Signaling Glutathione-mediated Detoxification
Estrogen-mediated S-phase Entry Hereditary Breast Cancer Signaling
GADD45 Signaling Neuroprotective Role of THOP1 in Alzheimer’s Disease
Caveolar-mediated Endocytosis Signaling JAK/Stat Signaling
Graft-versus-Host Disease Signaling Protein Ubiquitination Pathway
LXR/RXR Activation PI3K/AKT Signaling
Oncostatin M Signaling CDK5 Signaling
Autoimmune Thyroid Disease Signaling Role of IL-17A in Arthritis
Cell Cycle Regulation by BTG Family Proteins Aryl Hydrocarbon Receptor Signaling
ATM Signaling Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis
Down-regulated
FXR/RXR Activation
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study applied several DEG algorithms designed for
either microarray or RNA-Seq data. Two of the most
widely used microarray DEG algorithms in recent years,
SAM and eBayes, are included in this study. The classi-
cal T-test, which is known to perform relatively poorly
in microarray analysis was also evaluated as a “control”
method [41]. While microarray data produces a continu-
ous intensity, which commonly follows a log-normal dis-
tribution [42], the RNA-Seq gene expression level is
discrete or digital in nature. The microarray DEG algo-
rithms are based on continuous distribution of random
variables (after log transformation of the probe hybridi-
zation intensities). On the other hand, RNA-Seq DEG
algorithms are rapidly evolving. The earlier studies
mostly relied on algorithms assuming a Poisson distribu-
tion on the gene counts [1,13,39] while the more recent
methods utilized a negative binomial model which was
considered better than Poisson assumption in explaining
biological variability of the RNA-Seq data [28,43]. This
study considers several of the currently used, popular
RNA-Seq DEG algorithms: Cuffdiff, baySeq and DESeq
which are roughly based on the negative binomial mod-
eling of RNA-Seq data and the nonparametric SAMSeq
and NOISeq methods, which are relatively model-free.
Each of the methods has its own virtue and relevance:
the Cuffdiff method is built to incorporate biological
variability information (e.g. isoforms and fragment
assignment uncertainty) from the initial short reads
input. In baySeq algorithm, the estimate of significance
is based on an empirical Bayes approach, which ranks
the DEGs by posterior probabilities of the treatment
group. DESeq assumes a locally linear relationship
between variance and mean expression level. The SAM-
Seq algorithm, on the other hand, differs from the afore-
mentioned algorithms by identifying DEGs using a
Wilcoxon rank based nonparametric approach, which is
relatively free from model biases. Lastly, the NOISeq
algorithm evaluates the log-ratio of normalized counts
(M value) versus their absolute difference (D value) and
determined their differential significance by comparing
to the noise distribution, and is designed to overcome
the sequencing depth dependency commonly seen in
other DEG methods.
Our simulation experiment using preset, true-positive
genes at a minimal fold change of 2, demonstrated max-
imal cross-platform overlaps in the DEG lists generated
by two of the RNA-Seq algorithms, baySeq and DESeq,
and by two microarray methods, eBayes and SAM
(Table 2). These observations are consistent with our
results obtained using the HT-29 experimental data.
Note however, that we were not able to evaluate the
Cuffdiff algorithm using the simulated dataset. When
the sensitivity of all the DEG methods were also exam-
ined in our study, the results showed that baySeq
performed best among all RNA-Seq algorithms evalu-
ated, in identifying true positive genes at each 95% mini-
mal fold-change level. This observation is consistent
with a previous study in which baySeq was found super-
ior in ranking genes by significance to be declared [35].
DESeq tails immediately after baySeq in sensitivity
curves and performed comparably well at lower fold
change levels (e.g. log2 fold change ~ 1.5). The microar-
ray DEG algorithms, SAM and eBayes, were generally
found less sensitive than RNA-Seq programs.
With respect to FDR evaluation, however, baySeq
resulted in more false positive calls than most of the
other RNA-Seq algorithms except for NOISeq, especially
when the 95% minimum fold changes of true positive
genes are higher (Figure 3B, right section). DESeq con-
stantly results in the lowest FDR among all the RNA-Seq
algorithms evaluated in the simulation experiments, indi-
cating its superior reliability. The NOISeq showed a very
poor performance on FDR evaluation curve particularly
with lower 95% minimal fold change thresholds (Figure
3B, left section), reflecting the fact that NOISeq’s DEG
discerning power by comparing noise distribution against
a true signal was seriously compromised when the ‘true
difference’ is less remarkable. In practice, it is of theoreti-
cal importance to weigh more on preventing false posi-
tives than false negatives; we thus favor DESeq over
Bayseq in RNA-Seq analysis as the former method con-
trols FDR better than the latter in higher differential sig-
nificance level (Figure 3B, right section).
Of the two microarray DEG algorithms, SAM slightly
outperforms Ebayes in both sensitivity and FDR evalua-
tion. The traditional T-test with BH correction, not sur-
prisingly, showed a very poor performance in identifying
true positives, probably due to its inappropriate inde-
pendence assumption. When we view our results from
the perspective of platform comparison, it is generally
expected that DESeq and SAM can lead to consistent
and reasonable DEG results – an observation which is
exactly reflected in our HT-29 experiment (Table 1).
Finally, to begin to address the biological significance
of these studies, we undertook to validate that treatment
of HT-29 colon cancer cells with 5 μM 5-Aza would
relieve suppression of SPARC gene expression. While
this anticipated outcome was confirmed using both the
RNA-Seq data and qRT-PCR data, it was not observed
in the microarray data. In addition a higher percentage
of other DEGs identified using both platforms or RNA-
Seq only was confirmed by qRT-PCR than the DEGs
identified using microarray alone.
Conclusions
A strong correlation of genomic expression profiles was
observed between the microarray and RNA-Seq platforms
with the latter technology detecting more genes across the
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genome. Remarkable differences between the two platforms
in terms of (1) the existence of both fixed and proportional
biases detected by the errors-in-variable (EIV) regression
model, and (2) discrepancies in DEG identification have
been discovered in our study. We further confirmed that
the DEG discrepancies are mostly related to the different
algorithms used for both platforms. Among all the DEG
algorithms surveyed in this study, the largest cross-platform
overlaps were observed between the DEG lists generated by
two RNA-Seq algorithms, baySeq and DESeq, and the DEG
lists generated by two microarray algorithms, SAM and
eBayes, from the HT-29 experimental dataset. The simula-
tion studies, which did not include evaluation of Cuffdiff,
indicate that the the DESeq algorithm outperformed the
other RNA-Seq algorithms, based upon the combined con-
siderations of sensitivity and false discovery rate. DESeq
also demonstrated the highest overlap rate with the DEG
list generated by SAM from the microarray data. Overall,
the nonparametric based DEG methods such as SAMSeq
or NOISeq exhibited suboptimal performance compared to
their parametric counterparts, partly due to the limited
number of replicates. QRT-PCR validated a higher percen-
tage of the DEGs identified by both platforms and RNA-
Seq only, than the DEGs identified by microarray only.
Finally, while there were common IPA canonical pathways
identified by both microarray and RNA-Seq data, a large
number of additional canonical pathways were identified by
RNA-Seq data alone. No additional canonical pathways
were identified by microarray data alone.
Additional material
Additional file 1: Table of ABI Taqman Assay Kit IDs used in qRT-
PCR assays. The list of 13 genes selected by majority vote on platform
specific DEG methods plus GAPDH and SPARC are included in this table.
Additional file 2: Table of DEGs for each algorithm. In this file, each
gene that was significant in at least one algorithm is shown with
corresponding fold change. NA under an algorithm indicates the gene is
not included in the DEG list generated by that algorithm. Up-regulated
and Down-regulated genes are in separate sheets. Log2 scaled
normalized gene expression intensities are shown for each gene on both
microarray and RNA-Seq platform.
Additional File 3: Table of significant pathway for both up and down
regulated DEGs. Pathways that were at least significant in one algorithm
are shown in this file. If a pathway is marked as significant in an algorithm,
the corresponding DEGs detected by that algorithm are included; otherwise
the cell is left blank. Both up-regulated and down-regulated pathways are
shown in this file, while down-regulated pathways are bolded.
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